MarkIt to Market® - June 2020: USPTO COVID-19 Prioritized Trademark Examination Program

Sterne, Kessler, Goldstein & Fox P.L.L.C.
Contact

Sterne, Kessler, Goldstein & Fox P.L.L.C.

As of June 16, 2020, the U.S. Patent and Trademark Office has implemented a program to prioritize the examination of trademark applications that cover goods and services that help prevent, diagnose, treat, or cure COVID-19. The following qualifying COVID-19 medical goods or services may be eligible for prioritized examination:

  • Pharmaceutical products or medical devices such as diagnostic tests, ventilators, and personal protective equipment, including surgical masks, face shields, gowns, and gloves, that are intended to prevent, diagnose, treat or cure COVID-19 and are subject to approval by the U.S. Food and Drug Administration (FDA) – including
    • Applications for Investigational New Drug (IND),
    • Investigational Device Exemption (IDE),
    • New Drug Application (NDA),
    • Biologics License Application (BLA),
    • Premarket Approval (PMA), or
    • Emergency Use Authorization (EUA).
  • Medical services or medical research services for the prevention, diagnosis, treatment of, or cure for COVID-19.

In order to request prioritized treatment, applicants must first file the application and then file a petition to the Director requesting that the initial examination of the application be advanced. The USPTO is waiving its normal petition fee under the prioritized examination program.
 
The petition must include a statement of facts, supported by an affidavit or declaration under 37 CFR§ 2.20, listing (1) the applicant’s COVID-19 related goods and services, (2) an explanation of why they qualify for prioritized examination, and (3) the section of the Code of Federal Regulations (CFR) that regulates the goods and services. If granted, the process should expedite examination by approximately two months.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Sterne, Kessler, Goldstein & Fox P.L.L.C. | Attorney Advertising

Written by:

Sterne, Kessler, Goldstein & Fox P.L.L.C.
Contact
more
less

Sterne, Kessler, Goldstein & Fox P.L.L.C. on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.